BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27938705)

  • 1. Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development.
    Oliver LD; Earnhart CG; Virginia-Rhodes D; Theisen M; Marconi RT
    Vet J; 2016 Dec; 218():27-33. PubMed ID: 27938705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses.
    Izac JR; Camire AC; Earnhart CG; Embers ME; Funk RA; Breitschwerdt EB; Marconi RT
    Vaccine; 2019 Apr; 37(17):2401-2407. PubMed ID: 30922701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.
    Camire AC; Hatke AL; King VL; Millership J; Ritter DM; Sobell N; Weber A; Marconi RT
    Vet J; 2021 Jul; 273():105676. PubMed ID: 34148599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tick-Tattoo: DNA Vaccination Against
    Klouwens MJ; Trentelman JJA; Wagemakers A; Ersoz JI; Bins AD; Hovius JW
    Front Immunol; 2021; 12():615011. PubMed ID: 33717102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.
    Rhodes DV; Earnhart CG; Mather TN; Meeus PF; Marconi RT
    Vet J; 2013 Nov; 198(2):412-8. PubMed ID: 23962611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
    LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
    Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and optimization of OspC chimeritope vaccinogens for Lyme disease.
    Izac JR; O'Bier NS; Oliver LD; Camire AC; Earnhart CG; LeBlanc Rhodes DV; Young BF; Parnham SR; Davies C; Marconi RT
    Vaccine; 2020 Feb; 38(8):1915-1924. PubMed ID: 31959423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of horses with Lyme vaccines for dogs induces short-lasting antibody responses.
    Guarino C; Asbie S; Rohde J; Glaser A; Wagner B
    Vaccine; 2017 Jul; 35(33):4140-4147. PubMed ID: 28668566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
    Izac JR; Oliver LD; Earnhart CG; Marconi RT
    Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
    O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
    Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response.
    Earnhart CG; Buckles EL; Dumler JS; Marconi RT
    Infect Immun; 2005 Dec; 73(12):7869-77. PubMed ID: 16299277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
    Lovrich SD; Jobe DA; Schell RF; Callister SM
    Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody profiling of a Borreliella burgdorferi (Lyme disease) C6 antibody positive, symptomatic Rottweiler and her pups.
    Hatke AL; Green DR; Stasiak K; Marconi RT
    Vet J; 2020 Aug; 262():105504. PubMed ID: 32792093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum.
    Wagner B; Freer H; Rollins A; Erb HN
    Vet Immunol Immunopathol; 2011 Apr; 140(3-4):190-8. PubMed ID: 21208663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences.
    Earnhart CG; Marconi RT
    Hum Vaccin; 2007; 3(6):281-9. PubMed ID: 17921702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in horses and its validation using Bayesian and conventional statistical methods.
    Wagner B; Freer H; Rollins A; Erb HN; Lu Z; Gröhn Y
    Vet Immunol Immunopathol; 2011 Dec; 144(3-4):374-81. PubMed ID: 21890217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains.
    Earnhart CG; Buckles EL; Marconi RT
    Vaccine; 2007 Jan; 25(3):466-80. PubMed ID: 16996663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines.
    Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM
    Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.